A phase I/II trial for house dust mite rhinitis with a new improved hdm-ASIT+ product.
Phase of Trial: Phase I/II
Latest Information Update: 01 Feb 2018
Price : $35 *
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Rhinoconjunctivitis
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2018 New trial record
- 25 Jan 2018 According to an ASIT biotech media release, this trial is due to be initiated in early 2019.